A case report of Gitelman syndrome in children.
Study Design
- Study Type
- Case Reports
- Population
- Hypokalemia
- Duration
- 13.0 weeks
- Intervention
- A case report of Gitelman syndrome in children. 3 g
- Comparator
- None
- Primary Outcome
- pain reduction
- Effect Direction
- Mixed
- Risk of Bias
- High
Abstract
RATIONALE: Giltelman syndrome (GS) is an autosomal recessive infectious disease, which is caused by the mutation of SLC12A3 gene encoding thiazide diuretic sensitive sodium chloride cotransporter located in the distal convoluted tubule of the kidney. PATIENT CONCERNS: A 7-year-old and 3-month-old male patient has poor appetite, slow growth in height and body weight since the age of 3, body weight: 16 kg (-3 standard deviation), height: 110 cm (-3 standard deviation), normal exercise ability and intelligence. One year ago, he was diagnosed with hypokalemia. After potassium supplement treatment, the blood potassium returned to normal. The patient developed abdominal pain, vomiting, limb weakness, and tetany 1 day before admission. DIAGNOSES: After admission examination, the patient was found to have hypokalemia (2.27-2.88 mmol/L), hypomagnesemia (0.47 mmol/L), hypophosphatemia (1.17 mmol/L), hypocalcemia (1.06 mmol/24 hours), and metabolic alkalosis (PH 7.60). The blood pressure is normal, and the concentration of aldosterone is 791.63 pg/mL. The adrenocorticotropic hormone and cortisol detected at 8 am are 4.95 pmol/L and 275.09 nmol/L, respectively. Twenty-four hours of urine potassium is 32.52 mmol. Gene sequencing results showed 2 pathogenic variants in the GS-related SLC12A3 gene, which are related to the phenotype of the subject. INTERVENTIONS: After admission, the patients were given potassium and magnesium supplements, as well as oral spironolactone. The symptoms of limb weakness and tetany were significantly relieved. After discharge, the patients continued to maintain treatment to keep the blood potassium at more than 3.0 mmol/L, and the blood magnesium at more than 0.6 mmol/L. OUTCOMES: Follow-up at 1 month after discharge, in the patient's self-description, he had no symptoms such as limb weakness and tetany, and his height was increased by 1 cm and the body weight increased by 1.5 kg. LESSONS: For patients with hypokalemia, hypomagnesemia, and metabolic alkalosis, the possibility of GS should be given priority. After the diagnosed by gene sequencing of SLC12A3 gene, potassium and magnesium supplementation could significantly improve symptoms.
TL;DR
For patients with hypokalemia, hypomagnesemia, and metabolic alkalosis, the possibility of GS should be given priority and potassium and magnesium supplementation could significantly improve symptoms.
Full Text
Used In Evidence Reviews
Similar Papers
Journal of internal medicine · 2005
Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise.
Acta bio-medica : Atenei Parmensis · 2018
Nutritional prevention of cognitive decline and dementia.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2018
Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.
Dermatologic clinics · 2010
Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.
American journal of kidney diseases : the official journal of the National Kidney Foundation · 2001
Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma.
American family physician · 2019